ArticleCancers2024

Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.

Su Yin Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.